RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer
RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET [Yahoo! Finance]
RenovoRx, Inc. (NASDAQ: RNXT) had its price target raised by analysts at Ascendiant Capital Markets from $8.25 to $9.00. They now have a "buy" rating on the stock.
RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET
RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System [Yahoo! Finance]